Citations

Showing 10 of 108104 citations.

MULTIMORBIDITY IN POPULATION STUDIES: THE ROCHESTER EPIDEMIOLOGY PROJECT
Rocca, Walter A.

Mayo Clinic

Innovation in Aging | November 10, 2018 | Volume: 2 | Issue: suppl_1 | Pages: 607-607

10.1093/geroni/igy023.2256 Get It

A PILOT STUDY OF A MULTICOMPONENT OBESITY INTERVENTION IN OLDER, RURAL ADULTS WITH OBESITY
Pidgeon, Dawna , Jensen, Michael D. , Clark, Matthew M. , MacKenzie, Todd A. , Bartels, Stephen J. , Batsis, John A. , Al-Nimr, Rima Itani , Cook, Summer B.

Mayo Clinic

Innovation in Aging | November 10, 2018 | Volume: 2 | Issue: suppl_1 | Pages: 305-305

10.1093/geroni/igy023.1120 Get It

Needle electromyography and histopathologic correlation in myopathies
Sener, Uğur , Martinez‐Thompson, Jennifer M. , Laughlin, Ruple S. , Dimberg, Elliot L., Rubin, Devon I., Martinez-Thompson, Jennifer, Sener, Ugur

Mayo Clinic

Muscle & Nerve | November 10, 2018 | Volume: 59 | Issue: 3 | Pages: 315-320

10.1002/mus.26381 | PMID 30414326 Get It

ABSTRACT Introduction Needle electromyography (EMG) findings help confirm myopathy and may indicate specific pathologic changes on muscle biopsy. Methods We conducted a retrospective chart review of 218 consecutive patients referred for muscle biopsy. Presence of specific needle EMG findings was correlated with pathologic findings of inflammation, necrosis, splitting, and vacuolar changes. Sensitivity, specificity, and positive and negative predictive values of specific EMG findings for pathologic changes were calculated. Results Short‐duration motor unit potentials (MUP) were sensitive (83%–94%) but not specific (34%–49%) for pathologic changes. Fibrillation potentials were 65%–74% sensitive and 58%–81% specific for inflammation, necrosis, splitting, or vacuolar changes. The absence of fibrillation potentials had high negative predictive value (82%–93%) for inflammation, splitting, or vacuolar changes. Discussion Fibrillation potentials and short‐duration MUPs predict pathologic changes of muscle fiber necrosis, splitting, and/or vacuolar changes (as seen with inflammatory myopathies and muscular dystrophies). Absence of fibrillation potentials suggests other myopathologic changes (e.g., congenital myopathy). Muscle Nerve 59 :315–320, 2019
ENGAGING FAMILY CAREGIVERS TO IMPROVE HEALTH CARE DELIVERY: ESTABLISHING CLINICAL BEST PRACTICES
Griffin, Josephine, Bangerter, Lauren R. , Havyer, Rachel D. , Comer, Meryl, Biggar, Virginia , Frangiosa, Terry

Mayo Clinic

Innovation in Aging | November 10, 2018 | Volume: 2 | Issue: suppl_1 | Pages: 125-126

10.1093/geroni/igy023.461 Get It

INSIGHTS FROM THE STATES: FELLOW EXPERIENCES IN STATE UNITS ON AGING, DEPARTMENTS OF HEALTH, AND OTHER LOCAL EFFORTS
Leppin, Aaron L.

Mayo Clinic

Innovation in Aging | November 10, 2018 | Volume: 2 | Issue: suppl_1 | Pages: 203-203

10.1093/geroni/igy023.746 Get It

Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests
Stricker, Nikki H. , Lundt, Emily S. , Edwards, Kelly K., Kremers, Walter K. , Roberts, Rosebud O., Petersen, Ronald C. , Mielke, Michelle M. , Mielke, Michelle M , Kremers, Walter K , Machulda, Mary M. , Knopman, David S. , Stricker, Nikki H , Lundt, Emily S

Mayo Clinic

The Clinical Neuropsychologist | November 10, 2018 | Volume: 33 | Issue: 6 | Pages: 1102-1126

10.1080/13854046.2018.1519085 | PMID 30417735 Get It

Exercise-induced arterial hypoxemia; some answers, more questions
Dominelli, Paolo B. , Sheel, A. William

Mayo Clinic

Applied Physiology, Nutrition, and Metabolism | November 9, 2018 | Volume: 44 | Issue: 6 | Pages: 571-579

10.1139/apnm-2018-0468 | PMID 30412430 Get It

Exercise-induced arterial hypoxemia (EIAH) is characterized by the decrease in arterial oxygen tension and oxyhemoglobin saturation during dynamic aerobic exercise. Since the time of the initial observations, our knowledge and understanding of EIAH has grown, but many unknowns remain. The purpose of this review is to provide an update on recent findings, highlight areas of disagreement, and identify where information is lacking. Specifically, this review will place emphasis on (i) the occurrence of EIAH during submaximal exercise, (ii) whether there are sex differences in the development and severity of EIAH, and (iii) unresolved questions and future directions.
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
Pardanani, Animesh , Shah, Sahrish, Mannelli, Francesco , Elala, Yoseph, Patnaik, Mrinal M. , Gangat, Naseema , Reichard, Kaaren K. , Hanson, Curtis A. , Tefferi, Ayalew , Elala, Yoseph C, Lasho, Terra L. , Mannelli, Francesco , Guglielmelli, Paola , Ketterling, Rhett P. , Vannucchi, Alessandro M.

Mayo Clinic

Blood Advances | November 9, 2018 | Volume: 2 | Issue: 21 | Pages: 2964-2972

10.1182/bloodadvances.2018026245 | PMID 30413432 Get It

Abstract Systemic mastocytosis (SM) is a clinically heterogeneous disease with prognosis chiefly assigned based on World Health Organization (WHO) morphologic subclassification. We assessed the feasibility of developing contemporary risk models for SM based on clinical and integrated clinical-genetics information. Diagnosis of SM was per WHO criteria, and karyotype and next-generation sequencing data were available in a subset of the total 580 patients (median age, 55 years; range, 18-88 years) seen at the Mayo Clinic between 1968 and 2015. Morphologic subcategories were indolent/smoldering in 291 (50%) and “advanced” in 289 (50%): SM with an associated hematological neoplasm in 199, aggressive SM in 85, and mast cell leukemia in 5. Multivariable analysis of clinical variables identified age >60 years, advanced SM, thrombocytopenia <150 × 109/L, anemia below sex-adjusted normal, and increased alkaline phosphatase (ALP) as independent risk factors for survival; respective hazard ratios (HRs) 95% confidence intervals (95% CIs) were 2.5 (1.9-3.4), 2.7 (1.8-4.0), 2.5 (1.9-3.4), 2.2 (1.6-3.1), and 2.1 (1.5-3.0). In addition, ASXL1 (HR, 4.5; 95% CI, 2.6-7.6), RUNX1 (HR, 4.3; 95% CI, 1.3-10.8), and NRAS (HR, 5.0, 95% CI, 1.5-13.2) mutations were independently associated with inferior survival. Combined clinical, cytogenetic, and molecular risk factor analysis confirmed the independent prognostic contribution of adverse mutations (2.6, 1.6-4.4), advanced SM (4.0, 1.8-10.0), thrombocytopenia (2.8, 1.7-4.5), increased ALP (2.1, 1.2-4.0), and age >60 years (2.2, 1.3-3.6). These data were subsequently used to develop clinical and hybrid clinical-molecular risk models. The current study advances 2 complementary risk models for SM and highlights the independent prognostic contribution of mutations.
Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging tools
Johnson, Derek R. , Ruff, Michael W. , Fang, Shanna, Morris, Pearse , Johnson, Derek R , Guérin, J. , Hunt, Christopher H. , Morris, Jonathan M. , Kaufmann, Timothy J.

Mayo Clinic

The British Journal of Radiology | November 9, 2018 | Volume: 92 | Issue: 1094 | Pages: 20180730

10.1259/bjr.20180730 | PMID 30412421 Get It

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials
Duma, Narjust , Kothadia, Sejal, Azam, Tariq U. , Yadav, Siddhartha , Aguilera, Jesus Vera, Vélez, Miguel González , Hálfdánarson, Þorvarður R. , Molina, Julian R. , Mansfield, Aaron S. , Adjei, Alex A. , Vera Aguilera, Jesus, Hubbard, Joleen M. , Mansfield, Aaron S , Yadav, Siddhartha , Halfdanarson, Thorvardur R , Paludo, Jonas , Go, Ronald S.

Mayo Clinic

The Oncologist | November 9, 2018 | Volume: 24 | Issue: 1 | Pages: 96-102

10.1634/theoncologist.2017-0687 | PMID 30413668 Get It

Abstract Background Early phase clinical trials evaluate the safety and efficacy of new treatments. The exclusion/inclusion criteria in these trials are usually rigorous and may exclude many patients seen in clinical practice. Our objective was to study the comorbidities limiting the participation of patients with breast, colorectal, or lung cancer in clinical trials. Materials and Methods We queried ClinicalTrials.gov on December 31, 2016. We reviewed the eligibility criteria of 1,103 trials. Logistic regression analyses were completed, and exclusion was studied as a binary variable. Results Out of 1,103 trials, 70 trials (6%) excluded patients >75 years of age, and 45% made no reference to age. Eighty-six percent of trials placed restrictions on patients with history of prior malignancies. Regarding central nervous system (CNS) metastasis, 416 trials (38%) excluded all patients with CNS metastasis, and 373 (34%) only allowed asymptomatic CNS metastasis. Regarding chronic viral infections, 347 trials (31%) excluded all patients with human immunodeficiency virus, and 228 trials (21%) excluded all patients with hepatitis B or C infection. On univariate analysis, chemotherapy trials were more likely to exclude patients with CNS metastasis and history of other malignancies than targeted therapy trials. Multivariate analysis demonstrated that industry-sponsored trials had higher odds of excluding patients with compromised liver function. Conclusion Many clinical trials excluded large segments of the population of patients with cancer. Frequent exclusion criteria included patients with CNS metastasis, history of prior malignancies, and chronic viral infections. The criteria for participation in some clinical trials may be overly restrictive and limit enrollment. Implications for Practice The results of this study revealed that most early phase clinic trials contain strict exclusion criteria, potentially excluding the patients who may be more likely to represent the population treated in clinical settings, leaving patients susceptible to unintended harm from inappropriate generalization of trial results. Careful liberalization of the inclusion/exclusion criteria in clinical trials will allow investigators to understand the benefits and drawbacks of the experimental drug for a broader population, and possibly improve recruitment of patients with cancer into clinical trials.